Human Interleukin-1 receptor antagonist Recombinant
Catalog no. :
Optimized DNA sequence encoding Human interleukin-1 receptor antagonist mature chain was expressed in Escherichia Coli.
Human interleukin-1 receptor antagonist is generated by the proteolytic removal of the signal peptide and propeptide.The molecule has a calculated molecular mass of approximately 17kDa.
Recombinant IL-1RA is a disulfide-linked monomer protein consisting of 153 amino acid residue subunits, and migrates as an approximately 17 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
>95%, as determined by SDS-PAGE and HPLC
The ED(50) was determined by the ability to inhibit the IL-1α mediated cell proliferation in a murine helper T cell line,for this effect, in the presence of 50 pg/mL of IL-1α, is typically 20 - 60 ng/mL.
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Recombinant Interleukin-1 receptor antagonist was lyophilized from a 0.2 μm filtered PBS solution pH 7.4.
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity.
Avoid repeated freeze/thaw cycles.
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
interleukin-1 receptor antagonist
IL1ra is found in the
conditioned medium of a
variety of cells and is
produced by macrophages,
The soluble form of IL1ra
has been shown to be
produced by hepatocytes, and
to be regulated by pro-
9e,11e-conjugated linoleic acid increases expression of the endogenous antiinflammatory factor, interleukin-1 receptor antagonist, in raw 264.7 cells
1861 - 1866.
sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
1663 - 1668.
an autoinflammatory disease with deficiency of the interleukin-1receptor antagonist
N. Engl. J. Med.,
2426 - 2437.
accelerated recovery from acute hypoxia in obese mice is due to obesity-associated up-regulation of interleukin-1 receptor antagonist Endocrinology,
2660 - 2667.
phosphate buffered saline containing calcium and magnesium elicits increased secretion of interleukin-1 receptor antagonist Lab Med,
290 - 293.